Sponsor or institution

Clinical trials and research at Syntrix Biosystems, INC.

• 2Clinical trials
• 6NIH research projects
• 1Country

All recruiting trials (2)

• Combining SX-682 with enzalutamide for men with advanced prostate cancer resistant to abiraterone

  This study is testing whether combining SX-682 with enzalutamide can help men with advanced prostate cancer that hasn't improved with abiraterone.

  Recruiting at 5 sites Phase 2 Syntrix Biosystems, Inc. · Los Angeles, California and 5 other locations · NCT06228053

• Treatment of Myelodysplastic Syndrome with SX-682 and Decitabine

  This study is testing a new treatment combining SX-682 and decitabine to see if it helps people with Myelodysplastic Syndromes feel better and improve their health.

  Recruiting at 7 sites Phase 1 Syntrix Biosystems, Inc. · Jacksonville, Florida and 6 other locations · NCT04245397

NIH-funded research (6)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• New combo therapy for advanced melanoma using SX-682 with nivolumab and relatlimab

  This grant tests a new combination treatment for advanced melanoma to see if it helps people whose cancer has progressed on prior immunotherapies.

  NIH research Syntrix Biosystems, INC. · Auburn, United States · NIH-11406776

• CXCR1/2 inhibitor plus enzalutamide for abiraterone-resistant metastatic prostate cancer

  A phase 2 study tests whether adding SX-682 to enzalutamide helps men with advanced prostate cancer that no longer responds to abiraterone.

  NIH research Syntrix Biosystems, INC. · Auburn, United States · NIH-11370143

• Dose expansion of SX-682 alone and with decitabine for myelodysplastic syndromes (MDS)

  A study to test higher doses of SX-682 alone and with decitabine in people with myelodysplastic syndromes to see if this combination can help control the disease.

  NIH research Syntrix Biosystems, INC. · Auburn, United States · NIH-11324659

• Investigating a new treatment for myelodysplastic syndromes using SX-682 and decitabine.

  This study is looking at a new drug called SX-682 to see how well it works on its own and with another treatment for people with myelodysplastic syndromes (MDS), which can sometimes lead to leukemia, and if you're part of this study, you'll get careful attention and support throughout your treatment.

  NIH research Syntrix Biosystems, INC. · Auburn, United States · NIH-11247621

• A new treatment for advanced prostate cancer that has stopped responding to abiraterone.

  This research is testing a new combination of medicines, SX-682 and enzalutamide, for men whose advanced prostate cancer has become resistant to abiraterone.

  NIH research Syntrix Biosystems, INC. · Auburn, United States · NIH-11114019

• Investigating a new treatment for men with advanced prostate cancer resistant to standard therapies

  This study is looking for men with advanced prostate cancer who haven't had success with common treatments to see if a new drug called SX-682, when combined with enzalutamide, can help improve their treatment results.

  NIH research Syntrix Biosystems, INC. · Auburn, United States · NIH-10884438

Quick answers

How many clinical trials run by Syntrix Biosystems, INC. are recruiting right now?

2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in United States. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →